Imatinib Unknown Status Phase 2 Trials for Myelogenous Leukemia, Chronic Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01503502A Phase II Study of Flumatinib Versus Imatinib to Treat Philadelphia Chromosome Positive Chronic Myelogenous Leukemia